Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NF1, NFNS, 4763, ENSG00000196712, P21359 AND Treatment
29 results:

  • 1. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency.
    Guerrini-Rousseau L; Pasmant E; Muleris M; Abbou S; Adam-De-Beaumais T; Brugieres L; Cabaret O; Colas C; Cotteret S; Decq P; Dufour C; Guillerm E; Rouleau E; Varlet P; Zili S; Vidaud D; Grill J
    J Med Genet; 2024 Jan; 61(2):158-162. PubMed ID: 37775264
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Molecular typing and mutational characterization of rectal neuroendocrine neoplasms.
    Duan X; Zhao M; Yin X; Mi L; Shi J; Li N; Han X; Han G; Wang J; Hou J; Yin F
    Cancer Med; 2023 Aug; 12(15):16207-16220. PubMed ID: 37387515
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. An MRI Deep Learning Model Predicts Outcome in Rectal cancer.
    Jiang X; Zhao H; Saldanha OL; Nebelung S; Kuhl C; Amygdalos I; Lang SA; Wu X; Meng X; Truhn D; Kather JN; Ke J
    Radiology; 2023 Jun; 307(5):e222223. PubMed ID: 37278629
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response.
    Lee TH; Jang BS; Chang JH; Kim E; Park JH; Chie EK
    Cancer Med; 2023 Jul; 12(14):15664-15675. PubMed ID: 37260182
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
    Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
    JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Anticancer drug resistance: An update and perspective.
    Nussinov R; Tsai CJ; Jang H
    Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
    Tak E; Kim M; Cho Y; Choi S; Kim J; Han B; Kim HD; Jang CS; Kim JE; Hong YS; Kim SY; Kim TW
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34779495
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
    Arai H; Elliott A; Millstein J; Xiu J; Ou FS; Innocenti F; Wang J; Battaglin F; Jayachandran P; Kawanishi N; Soni S; Zhang W; Sohal D; Goldberg RM; Hall MJ; Scott AJ; Khushman M; Hwang JJ; Lou E; Weinberg BA; Lockhart AC; Shields AF; Abraham JP; Magee D; Stafford P; Zhang J; Venook AP; Korn WM; Lenz HJ
    Oncogene; 2022 Jan; 41(2):260-267. PubMed ID: 34728807
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
    Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
    Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
    Naderi A
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (nf1).
    Shang L; Fang Z; Liu J; Du F; Jing H; Xu Y; Dong K; Zhang X; Wu H; Jing C; Li L
    BMC Cancer; 2019 Dec; 19(1):1196. PubMed ID: 31805970
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
    Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR treatment in colorectal cancer.
    Woolston A; Khan K; Spain G; Barber LJ; Griffiths B; Gonzalez-Exposito R; Hornsteiner L; Punta M; Patil Y; Newey A; Mansukhani S; Davies MN; Furness A; Sclafani F; Peckitt C; Jiménez M; Kouvelakis K; Ranftl R; Begum R; Rana I; Thomas J; Bryant A; Quezada S; Wotherspoon A; Khan N; Fotiadis N; Marafioti T; Powles T; Lise S; Calvo F; Guettler S; von Loga K; Rao S; Watkins D; Starling N; Chau I; Sadanandam A; Cunningham D; Gerlinger M
    Cancer Cell; 2019 Jul; 36(1):35-50.e9. PubMed ID: 31287991
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Neurofibromatosis type 1-associated multiple rectal neuroendocrine tumors: A case report and review of the literature.
    Xie R; Fu KI; Chen SM; Tuo BG; Wu HC
    World J Gastroenterol; 2018 Sep; 24(33):3806-3812. PubMed ID: 30197486
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Impact of Patient Age on Molecular Alterations of Left-Sided colorectal Tumors.
    Puccini A; Lenz HJ; Marshall JL; Arguello D; Raghavan D; Korn WM; Weinberg BA; Poorman K; Heeke AL; Philip PA; Shields AF; Goldberg RM; Salem ME
    Oncologist; 2019 Mar; 24(3):319-326. PubMed ID: 30018131
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. SMAD4 and nf1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
    Mei Z; Shao YW; Lin P; Cai X; Wang B; Ding Y; Ma X; Wu X; Xia Y; Zhu D; Shu Y; Fu Z; Gu Y
    BMC Cancer; 2018 Apr; 18(1):479. PubMed ID: 29703253
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A mutational comparison of adult and adolescent and young adult (AYA) colon cancer.
    Tricoli JV; Boardman LA; Patidar R; Sindiri S; Jang JS; Walsh WD; McGregor PM; Camalier CE; Mehaffey MG; Furman WL; Bahrami A; Williams PM; Lih CJ; Conley BA; Khan J
    Cancer; 2018 Mar; 124(5):1070-1082. PubMed ID: 29194591
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Rectal carcinoma and multiple gastrointestinal stromal tumors (GIST) of the small intestine in a patient with neurofibromatosis type 1: a case report.
    Hakozaki Y; Sameshima S; Tatsuoka T; Okuyama T; Yamagata Y; Noie T; Oya M; Fujii A; Ueda Y; Shimura C; Katagiri K
    World J Surg Oncol; 2017 Aug; 15(1):160. PubMed ID: 28835241
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.